Pfizer Inc. Stock
€22.49
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Pfizer
sharewise wants to provide you with the best news and tools for Pfizer, so we directly link to the best financial data sources.
Financials
News
BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM
BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment
Arvinas Q1 Earnings Call Highlights
Arvinas (NASDAQ:ARVN) said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel
The Dividend Safe Harbor: 2 Stocks to Watch
It’s been a lackluster year so far for U.S. equities. Year-to-date, the benchmark S&P 500 is slightly in the red, weighed down primarily by a selloff in mega-cap technology. What began as a pause
Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most
Pfizer Inc. (NYSE: PFE) helped boost the Dow Jones Industrial Average (DJIA) the day after delivering a double beat in its fourth-quarter earnings report.
Revenue of $17.56 billion topped
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All
After a lackluster first half of 2025, healthcare stocks staged a comeback, posting the best performance among the 11 S&P 500 sectors over the past six months.
In large part, that rebound was
This ETF Is Proof That the Healthcare Rebound Is Real
With well-publicized losses for companies including UnitedHealth Group (NYSE: UNH), Elevance Health (NYSE: ELV), and Wegovy and Ozempic maker Novo Nordisk (NYSE: NVO), the healthcare sector failed
These 3 Stocks Trade at Discounts the Market Won’t Ignore Forever
The S&P 500 wrapped up 2025 with a total return of about 18%, the third straight year above historical norms but a lower figure than the gangbusters 25% returns of 2023 and 2024. AI euphoria is
Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake
The market of 2025 will be remembered for its extremes. While investors poured billions into technology sector giants and companies manufacturing weight-loss drugs, traditional pharmaceutical
Pfizer Adds to Its Big Bet on Weight Loss Drugs
Health care stocks have been on a run lately, leading the S&P 500’s 11 sectors over the past three months with a gain of 11.55%. Unfortunately for some investors, that recent rally has not
This Healthcare Stock With 6%-Plus Yield: Is the Dividend Safe?
Pfizer (NYSE: PFE) is facing patent expirations for some of its biggest drugs. That's normal for a pharmaceutical company, but Pfizer doesn't appear to have any major new drugs to replace those
Why 1 Wall Street Analyst Thinks Pfizer (PFE) Stock Could Soar 38%
If you've spent any time reading about certain stocks, you'll have noticed that opinions among Wall Street analysts can vary widely. Because there's no way to definitively determine where a stock
Eli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here's What You Need to Know.
When you think of growth stocks, you may immediately think of technology. But this isn't the only field delivering significant revenue gains these days. In fact, you'll find one of the biggest
The Most Important Healthcare Stock You're Not Watching
A company with a $140 billion market cap is very large. It is also highly likely to be an important player in the industry where it competes. But that doesn't seem to matter today for Pfizer (NYSE:
The Most Undervalued Healthcare Stock in the S&P 500 Right Now
Shares of Bristol Myers Squibb (NYSE: BMY) are trading in a manner that evokes little confidence in the company's future growth.
The numbers suggest otherwise. At roughly 10 times forward earnings
3 Deeply Undervalued Stocks You Can Buy for Less Than $100 Right Now
Although the stock market may seem hot these days and largely overvalued, there are some gems you can find out there, with many stocks priced below $100. If you're a long-term investor, then three
Pfizer Just Locked In Its Next 5 Years of Growth -- Here's How
Anyone keeping tabs on Pfizer (NYSE: PFE) probably knows it still hasn't rekindled its glory days early in the COVID-19 pandemic. In 2022, it reported record-breaking revenue of just over $100
Should Eli Lilly Investors Worry About Its Newest Rival -- From Within?
Eli Lilly (NYSE: LLY) has become the leader in a market marching toward the $100 billion mark. I'm talking about the weight-loss drug market, expected to reach that level early next decade from a
3 Struggling Stocks That Could Make for Great Contrarian Buys
Buying stocks that are down and facing challenges can be difficult simply because you don't know if or when a turnaround may take place. It may require a great deal of patience to invest in a stock
Prediction: Pfizer Will Beat the Market Over the Next 5 Years
Pfizer (NYSE: PFE) stock reached all-time highs earlier this decade thanks to the company's dominance in the market for coronavirus vaccines and medicines. However, the pharmaceutical leader was
Is Pfizer a Buy, Sell, or Hold in 2026?
A few years ago, Pfizer (NYSE: PFE) looked unstoppable. The company generated more than $100 billion in annual revenue early in the pandemic, powered by its COVID-19 vaccine and antiviral treatment
Pfizer's Net Income Drops in Q1. Is Its Dividend Still Safe?
One of the best reasons to invest in Pfizer (NYSE: PFE) stock right now is for its dividend, which yields a mouth-watering rate of 6.7%. That's considerably higher than the lowly S&P 500 average of
Is This a Sign Pfizer's Aggressive Growth Strategy Is Paying Off?
Did you know that from 2022 to 2025, Pfizer (NYSE: PFE)'s top line declined by a mammoth 38%? Its revenue fell from more than $101 billion when its COVID vaccine and pill were in high demand to less
Could Buying This Beaten-Down Healthcare Stock Make You Rich If It Recovers?
Pfizer (NYSE: PFE) is in a difficult spot right now. It has a number of blockbuster drugs nearing the end of their patent protection, which will likely lead to material revenue declines. It has
Forget Eli Lilly: These 2 Stocks Have More Upside
Shares of Eli Lilly (NYSE: LLY) have risen 400% over the past five years. Novo Nordisk (NYSE: NVO) rose just 20% over the same span and is down 60% from its 2024 high. Pfizer (NYSE: PFE) has fallen
Pfizer's 6.5% Dividend Yield Looked Too Good to Be True -- but Management Just Silenced the Skeptics
The higher the dividend yield, the more investors tend to worry. Pfizer (NYSE: PFE) boasts a forward dividend yield of 6.5%, the highest yield among large-cap healthcare stocks. Unsurprisingly, some